Skip to content
HowShorted

INOVIO PHARMACEUTICALS, INC. short interest in 2023

In 2023, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 17.95% of shares outstanding on 13 Jan 2023 to 8.75% on 29 Dec 2023, a change of -9.20 percentage points. The year's high was 17.95% on 13 Jan 2023 and its low 5.56% on 29 Sep 2023, averaging 11.73% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.60 days on 30 Nov 2023. Full history: INOVIO PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INOVIO PHARMACEUTICALS, INC. in 2023

2023 in figures

Start of year
17.95% (13 Jan 2023)
End of year
8.75% (29 Dec 2023)
Change
-9.20 pp
High
17.95% (13 Jan 2023)
Low
5.56% (29 Sep 2023)
Average
11.73%
Highest days to cover
13.60 (30 Nov 2023)
SEC filings marked
8

Every report in 2023

INOVIO PHARMACEUTICALS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202317.95%9.66
31 Jan 202317.53%10.85
15 Feb 202316.20%7.87
28 Feb 202315.48%10.59
15 Mar 202315.19%9.7610-K filed, results (8-K)
31 Mar 202313.38%6.92
14 Apr 202315.24%4.27
28 Apr 202315.19%8.18
15 May 202315.09%7.8010-Q filed, results (8-K)
31 May 202316.45%3.98
15 Jun 202316.85%4.53
30 Jun 20239.27%1.28
14 Jul 20238.04%2.72
31 Jul 20238.30%6.91
15 Aug 20238.23%8.2610-Q filed, results (8-K)
31 Aug 20236.23%9.00
15 Sep 20235.83%6.27
29 Sep 20235.56%8.43
13 Oct 20239.59%2.74
31 Oct 20239.30%7.58
15 Nov 20239.50%11.8410-Q filed, results (8-K)
30 Nov 20239.42%13.60
15 Dec 20238.89%11.27
29 Dec 20238.75%9.64

See also: INOVIO PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.